Trained detection dogs distinguish between urine samples from healthy organisms and organisms with malignant tumors, suggesting that the volatile urine metabolome contains information about tumor progression. The aim of this study was to determine whether the stage of tumor growth affects the chemical differences in the urine of mice and to what extent the "olfactory image of disease" perceived by dogs coincides with the "image of disease" recorded by the mass spectrometer. We used a novel laser ionization mass spectrometry method and propose a mass spectrometric analysis without detailed interpretation of the spectrum of volatile metabolomes in urine. The mass spectrometer we use works without sample preparation and registers volatile organic compounds in air at room temperature without changing the pH of the sample, i.e. under conditions similar to those in which dogs solve the same problem. The experimental cancer models were male BDF-f1 hybrid mice transplanted with hepatocarcinoma tissue, and similar mice transplanted with healthy liver tissue were used as controls. Our data show that both dogs and our proposed laser mass spectrometry method are able to detect both the entire spectrum of volatile organic compounds associated with the disease and minor changes in this spectrum during its course.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095867 | PMC |
http://dx.doi.org/10.1038/s41598-022-11818-0 | DOI Listing |
J Clin Pathol
January 2025
Institute of Liver Studies, King's College Hospital, London, UK
Aims: To reveal clinicopathological characteristics of alcoholic foamy degeneration (AFD)-an uncommon form of alcoholic liver injury.
Methods: Clinicopathological features of AFD (n=9) were examined in comparison to those of severe alcoholic hepatitis (SAH; n=12).
Results: Patients with AFD presented with either biochemical liver dysfunction (n=1) or clinical jaundice (n=8).
J Immunother Cancer
January 2025
Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
Background: Numerous studies have demonstrated limited survival benefits of transarterial chemoembolization (TACE) alone in the treatment of intermediate-stage hepatocellular carcinoma (HCC) beyond up-to-seven criteria. The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has opened new avenues for HCC treatment. However, TACE combined with ICIs has not been investigated for patients with intermediate-stage HCC beyond the up-to-seven criteria.
View Article and Find Full Text PDFJAMA Netw Open
January 2025
Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio.
Importance: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease and is projected to become the leading indication for liver transplant (LT) in the US. Understanding its clinical burden can help to identify opportunities for prevention and treatment.
Objective: To project the burden of MASLD in US adults from 2020 to 2050.
Introduction: Chronic liver disease, a progressive deterioration of liver function, has become a significant health problem in the United States. According to the National Vital Statistics Report 2017 from the Center for Disease Control and Prevention, approximately 4.5 million adults have been diagnosed with chronic liver disease and cirrhosis (end-stage liver disease), which is 1.
View Article and Find Full Text PDFLiver Transpl
January 2025
Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco.
Background: Hepatocellular carcinoma (HCC) has become a leading indication for liver transplant (LT), with HCC registrants increasing more than six-fold in the past two decades, accompanied by a significant rise in older candidates. Given this trend and the influence of hepatitis C (HCV) treatments, updated data on aging and changing etiologies in older HCC patients are needed. This study examines age trends, clinical characteristics, and transplant outcomes by comparing older (70+), younger HCC patients, and non-HCC patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!